Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
07.10. | Ignota vacuums up Kronos Bio's drug programmes | - | pharmaphorum | ||
30.06. | Kronos Bio, Inc. - 15-12G, Securities registration termination | 1 | SEC Filings | ||
20.06. | NSE - Kronos Bio, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 8 | SEC Filings | ||
20.06. | Kronos Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
05.06. | Kronos Bio, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
08.05. | Kronos Bio, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
KRONOS BIO Aktie jetzt für 0€ handeln | |||||
05.05. | Concentra Biosciences Agrees to Acquire Kronos Bio | 1 | Contract Pharma | ||
01.05. | Concentra To Acquire Kronos Bio | 4 | RTTNews | ||
01.05. | Kronos Bio, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
01.05. | Kronos Bio stimmt Übernahme durch Concentra Biosciences zu | 11 | Investing.com Deutsch | ||
01.05. | Kronos Bio to be acquired by Concentra Biosciences | 1 | Seeking Alpha | ||
01.05. | Kronos Bio agrees to Concentra Biosciences acquisition | 1 | Investing.com | ||
01.05. | Kronos Bio, Inc.: Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right | 124 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. ("Kronos Bio") (Nasdaq: KRON), a biotechnology company that has been developing small molecule therapeutics to address cancers and... ► Artikel lesen | |
25.04. | Kronos Bio, Inc. - 10-K/A, Annual Report | 1 | SEC Filings | ||
18.03. | Kronos Bio, Inc.: Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results | 229 | GlobeNewswire (Europe) | SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a biopharmaceutical company, today reported fourth quarter and full year 2024 financial... ► Artikel lesen | |
27.11.24 | Kronos Bio, Inc.: Kronos Bio Announces CEO Transition and Reduction in Force | 297 | GlobeNewswire (Europe) | - Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO - - Deborah Knobelman, Ph.D., COO & CFO, is named President & Interim CEO - SAN MATEO, Calif. and CAMBRIDGE, Mass.... ► Artikel lesen | |
14.11.24 | Kronos Bio, Inc.: Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 | 177 | GlobeNewswire (Europe) | - Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo models... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 90,25 | +0,06 % | Diese Biotech-Aktie könnte Big Pharma das Fürchten lehren - mit einem oralen Abnehm-Blockbuster und Milliardenpotenzial bei MS! | Anzeige / WerbungWährend die Aktien von BioNTech und Evotec auf der Stelle treten, befindet sich BioNxt Solutions im Aufwärtstrend. Denn das Unternehmen mischt gerade Big Pharma auf. Die Ankündigung... ► Artikel lesen | |
EVOTEC | 6,576 | -4,36 % | Alternative zu BioNTec, Evotec und Co.: BioNxt Solutions überzeugt auf Investorenkonferenz und weckt Übernahmefantasie | Während die Aktien von BioNTech und Evotec auf der Stelle treten, befindet sich BioNxt Solutions im Aufwärtstrend. Denn das Unternehmen mischt gerade Big Pharma auf. Die Ankündigung, die Abnehmspritze... ► Artikel lesen | |
CUREVAC | 4,556 | -0,57 % | Erwerb von CureVac durch BioNTech freigegeben | Das Bundeskartellamt hat die geplante Übernahme von bis zu 100 Prozent der Anteile der CureVac N.V. (CureVac), Tübingen, durch die BioNTech SE (BioNTech), Mainz, freigegeben. Der beabsichtigte Erwerb... ► Artikel lesen | |
AMGEN | 256,05 | +0,02 % | Amgen And AstraZeneca's TEZSPIRE Approved For Epithelial-Driven Nasal Inflammation | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) and AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE (tezepelumab-ekko) as an add-on maintenance treatment... ► Artikel lesen | |
NOVAVAX | 6,951 | +0,20 % | NOVAVAX INC zündet den Turbo - jetzt wird's brisant! | ||
BIOGEN | 122,10 | -0,33 % | Biogen Inc.: LEQEMBI IQLIK(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" | TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts,... ► Artikel lesen | |
BIOFRONTERA | 2,690 | +0,37 % | BIOFRONTERA AG: Jetzt zündet die nächste Kursrakete! | ||
CORE ONE LABS | 0,079 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
REGENERON PHARMACEUTICALS | 492,00 | -0,71 % | Regeneron Says CHMP Recommends Libtayo For EU Approval As Adjuvant Treatment Of CSCC | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a... ► Artikel lesen | |
MAINZ BIOMED | 1,490 | +4,93 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed to Attend 2025 Maxim Growth Summit | Issuer: Mainz BioMed N.V.
/ Key word(s): Conference
Mainz Biomed to Attend 2025 Maxim Growth Summit
15.10.2025 / 15:01 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
VIKING THERAPEUTICS | 28,600 | -0,47 % | Pre-Q3 Earnings: Is Viking Therapeutics Stock a Portfolio Must-Have? | ||
INTELLIA THERAPEUTICS | 21,030 | -0,80 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
TEMPUS AI | 75,00 | -0,66 % | AKTIONÄR-Tipp Tempus AI lässt Biotech-Aktie explodieren | Der Megatrend Künstliche Intelligenz (KI) ist an den Börsen weiter in aller Munde. Einer der großen Gewinner der Entwicklung: Tempus AI. Das Unternehmen will mit seinen KI-gestützten Lösungen die Präzisionsmedizin... ► Artikel lesen | |
TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 5,602 | -1,34 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile | - Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio - - Solidifies double digit growth trajectory for HAE... ► Artikel lesen |